CVRX
CVRx, Inc.
$6.11
+0.04
(+0.66%)
Mkt Cap
162.13M
Volume
237,864
52W Range
4.37-11.3
Sector
Healthcare
Beta
0.87
EPS (TTM)
-2.02
P/E Ratio
-3.47
Revenue (TTM)
59.07M
Rev Growth (5Y)
+56.4%
EPS Growth (5Y)
N/A
Company Description
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 56.65M | 51.29M | 39.30M | 22.47M | 13.04M | 6.05M | 6.26M |
| Net Income | (53.31M) | (59.97M) | (41.20M) | (41.43M) | (43.08M) | (14.11M) | (14.63M) |
| EPS | -2.04 | -2.65 | -1.99 | -2.02 | -2.11 | -0.73 | -0.76 |
| Free Cash Flow | (40.75M) | (40.51M) | (39.61M) | (43.36M) | (28.91M) | (16.41M) | (12.89M) |
| FCF / Share | -1.56 | -1.79 | -1.91 | -2.11 | -1.40 | -42.39 | -26.71 |
| Operating CF | (40.17M) | (39.14M) | (39.02M) | (42.68M) | (27.73M) | (16.10M) | (12.79M) |
| Total Assets | 104.79M | 133.41M | 115.23M | 124.94M | 152.55M | 64.78M | 29.11M |
| Total Debt | 50.79M | 50.43M | 30.61M | 7.09M | 0 | 19.28M | 18.99M |
| Cash & Equiv | 75.71M | 105.93M | 90.57M | 106.19M | 142.07M | 59.11M | 25.74M |
| Book Value | 39.32M | 71.06M | 75.95M | 109.18M | 145.96M | (293.24M) | (279.04M) |
| Return on Equity | -1.36 | -0.84 | -0.54 | -0.38 | -0.30 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.77M | 16.02M | 14.69M | 13.59M | 12.35M | 15.34M | 13.37M | 11.81M | 10.77M | 11.30M | 10.51M | 9.50M |
| Net Income | (13.12M) | (11.93M) | (12.87M) | (14.74M) | (13.77M) | (10.65M) | (13.10M) | (14.03M) | (22.19M) | (9.16M) | (9.01M) | (11.65M) |
| EPS | -0.50 | -0.46 | -0.49 | -0.57 | -0.53 | -0.43 | -0.57 | -0.65 | -1.04 | -0.44 | -0.43 | -0.56 |
| Free Cash Flow | (12.29M) | (9.83M) | (10.00M) | (8.04M) | (12.88M) | (8.06M) | (10.45M) | (10.19M) | (11.81M) | (8.01M) | (8.16M) | (12.95M) |
| FCF / Share | -0.47 | -0.37 | -0.38 | -0.31 | -0.50 | -0.36 | -0.46 | -0.47 | -0.56 | -0.39 | -0.39 | -0.63 |
| Operating CF | (12.16M) | (9.76M) | (9.71M) | (7.94M) | (12.77M) | (8.01M) | (10.41M) | (9.83M) | (10.90M) | (7.84M) | (8.12M) | (12.81M) |
| Total Assets | 99.73M | 104.79M | 111.33M | 119.56M | 129.59M | 133.41M | 127.67M | 95.98M | 106.17M | 115.23M | 106.40M | 114.97M |
| Total Debt | 59.03M | 50.79M | 50.52M | 50.54M | 50.42M | 50.43M | 50.44M | 30.59M | 30.60M | 30.61M | 15.38M | 15.38M |
| Cash & Equiv | 72.30M | 75.71M | 85.12M | 95.03M | 102.67M | 105.93M | 100.16M | 70.40M | 80.11M | 90.57M | 82.99M | 90.81M |
| Book Value | 29.11M | 39.32M | 48.05M | 57.93M | 69.36M | 71.06M | 65.18M | 55.25M | 66.26M | 75.95M | 82.83M | 89.96M |
| Return on Equity | -0.45 | -0.30 | -0.27 | -0.25 | -0.20 | -0.15 | -0.20 | -0.25 | -0.33 | -0.12 | -0.11 | -0.13 |
CVRX News
CVRx to Present at the William Blair 46th Annual Growth Stock Conference
CVRx to Present at the William Blair 46th Annual Growth Stock Conference
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX)
CVRx, Inc. (CVRX) Q1 2026 Earnings Call Transcript
CVRx Q1 Earnings Call Highlights
CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates
CVRx Reports First Quarter 2026 Financial and Operating Results
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population